Form 4 for SUPN SUPERNUS PHARMACEUTICALS, INC.
Accepted 2025-01-29 00:00:00 ET · period of report 2025-01-27 · accession 0001628280-25-003018 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-01-29 | 2025-01-27+ | SUPN | Bhatt Padmanabh P. | CSO, SVP of IP | S - Sale+OE | $39.62 | -3,273 | 10.1K | -24% | -$129.7K |
| DM | 2025-01-29 | 2025-01-27+ | SUPN | Bhatt Padmanabh P. | CSO, SVP of IP | M - OptEx | $29.61 | +3,273 | 10.8K | +43% | +$96.9K |
| DM | 2025-01-29 | 2025-01-27+ | SUPN | Bhatt Padmanabh P. | CSO, SVP of IP | M - OptEx | $0.00 | -3,273 | 9,477 | -26% | $0 |
| D | 2025-01-29 | 2025-01-28 | SUPN | Bhatt Padmanabh P. | CSO, SVP of IP | A - Grant | $0.00 | +1,650 | 1,650 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-27 | S | D | 2,573 | $39.62 | 10,149 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.61 to $39.67. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| 2 | Common | Common Stock | 2025-01-28 | S | D | 700 | $39.62 | 10,149 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.61 to $39.63. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| 3 | Common | Common Stock | 2025-01-27 | M | A | 2,573 | $29.61 | 12,722 | D | — | — | (F1) Includes an aggregate of 470 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan. |
| 4 | Common | Common Stock | 2025-01-28 | M | A | 700 | $29.61 | 10,849 | D | — | — | |
| 5 | Derivative | Employee Stock Option (Right to Buy) | 2025-01-27 | M | D | 2,573 | $0.00 | 10,177 | D | $29.61 · — to 2031-02-19 | 2,573 Common Stock | (F4) The option vested in four equal installments beginning on February 19, 2022. |
| 6 | Derivative | Performance Share Units | 2025-01-28 | A | A | 1,650 | $0.00 | 1,650 | D | $0.00 · — to — | 1,650 Common Stock | (F5) On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. |
| 7 | Derivative | Employee Stock Option (Right to Buy) | 2025-01-28 | M | D | 700 | $0.00 | 9,477 | D | $29.61 · — to 2031-02-19 | 700 Common Stock | (F4) The option vested in four equal installments beginning on February 19, 2022. |